Thanks, Pfizer: Mylan execs in line for $71M-plus golden parachutes in Upjohn merger

29th October 2019 Uncategorised 0

When Mylan and Pfizer’s Upjohn business trumpeted their merger in July, it marked a major coup for the generics maker’s shareholders after a rough couple of years. Turns out the deal wasn’t just profitable for Mylan’s investors—it was also a big score for Mylan’s C-suite.

More: Thanks, Pfizer: Mylan execs in line for M-plus golden parachutes in Upjohn merger
Source: fierce